Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy.
Alberto Domingo López-MuñozJefferson J S SantosJonathan W YewdellPublished in: Proceedings of the National Academy of Sciences of the United States of America (2023)
We recently reported that SARS-CoV-2 nucleocapsid (N) protein is abundantly expressed on the surface of both infected and neighboring uninfected cells, where it enables activation of Fc receptor-bearing immune cells with anti-N antibodies (Abs) and inhibits leukocyte chemotaxis by binding chemokines (CHKs). Here, we extend these findings to N from the common cold human coronavirus (HCoV)-OC43, which is also robustly expressed on the surface of infected and noninfected cells by binding heparan sulfate/heparin (HS/H). HCoV-OC43 N binds with high affinity to the same set of 11 human CHKs as SARS-CoV-2 N, but also to a nonoverlapping set of six cytokines. As with SARS-CoV-2 N, HCoV-OC43 N inhibits CXCL12β-mediated leukocyte migration in chemotaxis assays, as do all highly pathogenic and common cold HCoV N proteins. Together, our findings indicate that cell surface HCoV N plays important evolutionarily conserved roles in manipulating host innate immunity and as a target for adaptive immunity.
Keyphrases
- sars cov
- cell surface
- respiratory syndrome coronavirus
- induced apoptosis
- endothelial cells
- cell cycle arrest
- binding protein
- induced pluripotent stem cells
- coronavirus disease
- pluripotent stem cells
- hiv infected
- high throughput
- dna binding
- transcription factor
- peripheral blood
- cell death
- signaling pathway
- protein protein
- amino acid